Synergistic Combination of Linezolid and Fosfomycin Closing Each Other's Mutant Selection Window to Prevent Enterococcal Resistance

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2021 Feb 26

PMID 33633692

Citations 12

Authors

Lifang Jiang

Na Xie

Mingtao Chen

Yanyan Liu

Shuaishuai Wang

Jun Mao

Jiabin Li

Xiaohui Huang

Affiliations

Soon will be listed here.

Abstract

Enterococci, the main pathogens associated with nosocomial infections, are resistant to many common antibacterial drugs including β-lactams, aminoglycosides, etc. Combination therapy is considered an effective way to prevent bacterial resistance. Preliminary studies in our group have shown that linezolid combined with fosfomycin has synergistic or additive antibacterial activity against enterococci, while the ability of the combination to prevent resistance remains unknown. In this study, we determined mutant prevention concentration (MPC) and mutant selection window (MSW) of linezolid, fosfomycin alone and in combination including different proportions for five clinical isolates of and characterized the resistance mechanism for resistant mutants. The results indicated that different proportions of linezolid combined with fosfomycin had presented different MPCs and MSWs. Compared with linezolid or fosfomycin alone, the combination can restrict the enrichment of resistant mutants at a lower concentration. A rough positive correlation between the selection index (SI) of the two agents in combination and the fractional inhibitory concentration index (FICI) of the combination displayed that the smaller FICI of linezolid and fosfomycin, the more probable their MSWs were to close each other. Mutations in ribosomal proteins (L3 and L4) were the mechanisms for linezolid resistant mutants. Among the fosfomycin-resistant mutants, only two strains have detected the MurA gene mutation related to fosfomycin resistance. In conclusion, the synergistic combination of linezolid and fosfomycin closing each other's MSW could effectively suppress the selection of enterococcus resistant mutants, suggesting that the combination may be an alternative for preventing enterococcal resistance. In this study, the resistance mechanism of fosfomycin remains to be further studied.

Citing Articles

Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice.

Ishak A, Mazonakis N, Spernovasilis N, Akinosoglou K, Tsioutis C J Antimicrob Chemother. 2024; 80(1):1-17.

PMID: 39471409 PMC: 11695898. DOI: 10.1093/jac/dkae380.

Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives.

Eleftheriotis G, Marangos M, Lagadinou M, Bhagani S, Assimakopoulos S Microorganisms. 2023; 11(12).

PMID: 38138148 PMC: 10745436. DOI: 10.3390/microorganisms11123004.

Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy.

Adefisoye M, Olaniran A JAC Antimicrob Resist. 2023; 5(6):dlad127.

PMID: 38089461 PMC: 10712721. DOI: 10.1093/jacamr/dlad127.

Antibacterial Activity of Surfactin and Synergistic Effect with Conventional Antibiotics Against Methicillin-Resistant Isolated from Patients with Diabetic Foot Ulcers.

Li Z, Li T, Tang J, Huang L, Ding Y, Zeng Z Diabetes Metab Syndr Obes. 2023; 16:3727-3737.

PMID: 38029000 PMC: 10674630. DOI: 10.2147/DMSO.S435062.

Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies.

Antonello R, Riccardi N, Saderi L, Sotgiu G Eur J Clin Microbiol Infect Dis. 2023; 43(1):17-31.

PMID: 37975976 DOI: 10.1007/s10096-023-04704-8.

References

Ni W, Cai X, Wei C, Di X, Cui J, Wang R . Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Braz J Infect Dis. 2015; 19(2):170-80. PMC: 9425407. DOI: 10.1016/j.bjid.2014.12.004. View

Xu X, Xu L, Yuan G, Wang Y, Qu Y, Zhou M . Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance. Sci Rep. 2018; 8(1):7237. PMC: 5940791. DOI: 10.1038/s41598-018-25714-z. View

Lee E, Caffrey A . Thrombocytopenia with Tedizolid and Linezolid. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740346. DOI: 10.1128/AAC.01453-17. View

Zou J, Xia Y . Molecular characteristics and risk factors associated with linezolid-resistant Enterococcus faecalis infection in Southwest China. J Glob Antimicrob Resist. 2020; 22:504-510. DOI: 10.1016/j.jgar.2020.03.027. View

Zinner S, Gilbert D, Lubenko I, Greer K, Firsov A . Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother. 2008; 61(3):629-35. DOI: 10.1093/jac/dkm542. View

Alieva K, Strukova E, Golikova M, Portnoy Y, Zinner S, Firsov A . Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid. J Antibiot (Tokyo). 2018; 71(5):514-521. DOI: 10.1038/s41429-017-0016-9. View

Suzuki S, Horinouchi T, Furusawa C . Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014; 5:5792. PMC: 4351646. DOI: 10.1038/ncomms6792. View

Sassi M, Guerin F, Zouari A, Beyrouthy R, Auzou M, Fines-Guyon M . Emergence of optrA-mediated linezolid resistance in enterococci from France, 2006-16. J Antimicrob Chemother. 2019; 74(6):1469-1472. DOI: 10.1093/jac/dkz097. View

Fu Z, Ma Y, Chen C, Guo Y, Hu F, Liu Y . Prevalence of Fosfomycin Resistance and Mutations in murA, glpT, and uhpT in Methicillin-Resistant Staphylococcus aureus Strains Isolated from Blood and Cerebrospinal Fluid Samples. Front Microbiol. 2016; 6:1544. PMC: 4707275. DOI: 10.3389/fmicb.2015.01544. View

10.

Gilmore M, Lebreton F, van Schaik W . Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era. Curr Opin Microbiol. 2013; 16(1):10-6. PMC: 3649759. DOI: 10.1016/j.mib.2013.01.006. View

11.

Vranakis I, Goniotakis I, Psaroulaki A, Sandalakis V, Tselentis Y, Gevaert K . Proteome studies of bacterial antibiotic resistance mechanisms. J Proteomics. 2013; 97:88-99. DOI: 10.1016/j.jprot.2013.10.027. View

12.

Canton R, Morosini M . Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev. 2011; 35(5):977-91. DOI: 10.1111/j.1574-6976.2011.00295.x. View

13.

Strukova E, Portnoy Y, Romanov A, Edelstein M, Zinner S, Firsov A . Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015; 60(3):1208-15. PMC: 4775939. DOI: 10.1128/AAC.02334-15. View

14.

Diez-Aguilar M, Morosini M, Tedim A, Rodriguez I, Aktas Z, Canton R . Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations. Antimicrob Agents Chemother. 2015; 59(10):6039-45. PMC: 4576056. DOI: 10.1128/AAC.00822-15. View

15.

Mendes R, Deshpande L, Jones R . Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat. 2014; 17(1-2):1-12. DOI: 10.1016/j.drup.2014.04.002. View

16.

Durao P, Balbontin R, Gordo I . Evolutionary Mechanisms Shaping the Maintenance of Antibiotic Resistance. Trends Microbiol. 2018; 26(8):677-691. DOI: 10.1016/j.tim.2018.01.005. View

17.

Alieva K, Golikova M, Portnoy Y, Dovzhenko S, Kobrin M, Zinner S . Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model. J Chemother. 2019; 30(6-8):364-370. DOI: 10.1080/1120009X.2018.1533267. View

18.

Hua R, Xia Y, Wu W, Yan J, Yang M . Whole transcriptome analysis reveals potential novel mechanisms of low-level linezolid resistance in Enterococcus faecalis. Gene. 2018; 647:143-149. DOI: 10.1016/j.gene.2018.01.008. View

19.

Qi C, Xu S, Wu M, Zhu S, Liu Y, Huang H . Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Larval Infection Model. Infect Drug Resist. 2019; 12:3497-3505. PMC: 6858807. DOI: 10.2147/IDR.S219117. View

20.

Sharma D, Garg A, Kumar M, Khan A . Proteome profiling of carbapenem-resistant K. pneumoniae clinical isolate (NDM-4): Exploring the mechanism of resistance and potential drug targets. J Proteomics. 2019; 200:102-110. DOI: 10.1016/j.jprot.2019.04.003. View